论文部分内容阅读
目的探讨替吉奥单药三线或多线治疗老年晚期非小细胞肺癌(NSCLC)的有效性及安全性。方法抽取2013年10月—2016年1月新乡医学院第三附属医院收治的66例老年晚期NSCLC患者,根据干预方式不同分为两组,每组33例。研究组采用替吉奥治疗,28 d为1个周期,共治疗2个周期;对照组给予最佳支持治疗措施。对比两组临床疗效、不良反应发生情况,依据QOL评分量表对两组治疗前后生活质量改善情况进行评定。通过SPSS19.0对数据进行分析,P<0.05为差异有统计学意义。结果研究组肿瘤控制率(63.64%)高于对照组(39.39%),差异有统计学意义(P<0.05);治疗前两组精神状态、社会功能、生理功能、总体健康评分对比差异无统计学意义(P>0.05),经治疗,研究组各指标评分高于对照组,差异有统计学意义(P<0.05);研究组白细胞减少发生率(33.33%)、血小板减少发生率(30.30%)、消化道反应发生率(36.36%)高于对照组(12.12%、9.09%、12.12%),差异有统计学意义(P<0.05)。结论采用替吉奥单药三线或多线治疗老年晚期NSCLC效果显著,可在一定程度改善患者生活质量,且不良反应均可耐受。
Objective To investigate the efficacy and safety of TGEO single or multi-line therapy for senile advanced non-small cell lung cancer (NSCLC). Methods Sixty-six elderly patients with advanced NSCLC who were admitted to the Third Affiliated Hospital of Xinxiang Medical College from October 2013 to January 2016 were divided into two groups (33 in each group). The study group used TIGO treatment, 28 d for a cycle, a total of 2 cycles; control group given the best supportive treatment. The clinical efficacy and adverse reactions were compared between the two groups, and the quality of life before and after treatment was evaluated according to the QOL scale. Data were analyzed by SPSS19.0, P <0.05 for the difference was statistically significant. Results The tumor control rate (63.64%) in the study group was significantly higher than that in the control group (39.39%) (P <0.05). There was no significant difference in mental status, social function, physiological function and overall health score between the two groups before treatment (P <0.05). After treatment, the score of each index in the study group was higher than that in the control group (P <0.05). The incidence of leukopenia (33.33%) and thrombocytopenia (30.30% ), The incidence of gastrointestinal reaction (36.36%) was higher than that of the control group (12.12%, 9.09%, 12.12%), the difference was statistically significant (P <0.05). Conclusion The treatment of elderly patients with advanced non-small cell lung cancer (NSCLC) with three-line or multi-line treatment of tigox is effective and can improve the quality of life of patients with some degree of adverse reactions.